Clinical Evaluation of Interferons in Malignant Melanoma
The evaluation of interferons in the treatment of malignant melanoma has been mainly in the treatment of advanced disease using interferons as the sole agent or in combination with other agents. Studies of the value of interferons as adjuvant therapy in high-risk primary melanoma patients are necess...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative dermatology 1990-12, Vol.95 (6), p.S185-S187 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S187 |
|---|---|
| container_issue | 6 |
| container_start_page | S185 |
| container_title | Journal of investigative dermatology |
| container_volume | 95 |
| creator | McLeod, G.R. Thomson, D.B. Hersey, P. |
| description | The evaluation of interferons in the treatment of malignant melanoma has been mainly in the treatment of advanced disease using interferons as the sole agent or in combination with other agents. Studies of the value of interferons as adjuvant therapy in high-risk primary melanoma patients are necessary, but no results have been published to date. Human interferon alpha produces low response rates as a sole agent, but in combination with cimetidine, a 30% response rate has been achieved. Recombinant alpha interferons give responses of 15%-20% in advanced melanomas, and combination with cimetidine does not enhance the response rate.
Recombinant alpha interferons have been used in combination with other interferons, cimetidine, monoclonal antibodies, and cytotoxics, with either no or small improvement in response rates. DTIC with recombinant interferon alpha-2a has been shown to produce objective response rates of 26%, with low toxicity and maintenance of quality of life. A randomized trial with DTIC as the sole agent, compared with combination treatment, is being conducted to determine the significance of this finding. |
| doi_str_mv | 10.1111/1523-1747.ep12875500 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1285083978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022202X9091218Z</els_id><sourcerecordid>1285083978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-74809113da0d68bb884726c2536f85e4e40460a21b41b29c69f5179e754066583</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouq7-A4VeBC_VSZqvXgRZ_AIXLwreQppOJdJN16QV_Pe27OLezGUg7zvvzDyEnFG4ouO7poIVOVVcXeGaMq2EANgjs7_vfTIDYCxnwN6PyHFKnwBUcqEPySFVQDXIGdGL1gfvbJvdfdt2sL3vQtY12VPoMTYYu5AyH7Klbf1HsKHPltja0K3sCTlobJvwdFvn5O3-7nXxmD-_PDwtbp9zJwTvc8U1lJQWtYVa6qrSmismHROFbLRAjhy4BMtoxWnFSifLRlBVohIcpBS6mJPLTe46dl8Dpt6sfHLYjltgNyQzXi5AF6WarHxjdbFLKWJj1tGvbPwxFMyEzExszMTG7JCNbefbCUO1wnrXtGE06hdb3aYRVBNtcD7tbKVkSjO-ywm2HyL-GYSkTBVTzs1GxxHXt8dokvMYHNY-outN3fn_F_0FWYqOzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1285083978</pqid></control><display><type>article</type><title>Clinical Evaluation of Interferons in Malignant Melanoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>McLeod, G.R. ; Thomson, D.B. ; Hersey, P.</creator><creatorcontrib>McLeod, G.R. ; Thomson, D.B. ; Hersey, P.</creatorcontrib><description>The evaluation of interferons in the treatment of malignant melanoma has been mainly in the treatment of advanced disease using interferons as the sole agent or in combination with other agents. Studies of the value of interferons as adjuvant therapy in high-risk primary melanoma patients are necessary, but no results have been published to date. Human interferon alpha produces low response rates as a sole agent, but in combination with cimetidine, a 30% response rate has been achieved. Recombinant alpha interferons give responses of 15%-20% in advanced melanomas, and combination with cimetidine does not enhance the response rate.
Recombinant alpha interferons have been used in combination with other interferons, cimetidine, monoclonal antibodies, and cytotoxics, with either no or small improvement in response rates. DTIC with recombinant interferon alpha-2a has been shown to produce objective response rates of 26%, with low toxicity and maintenance of quality of life. A randomized trial with DTIC as the sole agent, compared with combination treatment, is being conducted to determine the significance of this finding.</description><identifier>ISSN: 0022-202X</identifier><identifier>EISSN: 1523-1747</identifier><identifier>DOI: 10.1111/1523-1747.ep12875500</identifier><identifier>PMID: 1701806</identifier><identifier>CODEN: JIDEAE</identifier><language>eng</language><publisher>Danvers, MA: Elsevier Inc</publisher><subject>Adjuvants ; alpha -Interferon ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cimetidine ; Clinical trials ; Clinical Trials as Topic ; Cytotoxicity ; Dacarbazine - administration & dosage ; Dermatology ; Dose-Response Relationship, Drug ; Forecasting ; Humans ; Immunomodulators ; Interferon ; Interferon alpha-2 ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Interferons - therapeutic use ; Medical sciences ; Melanoma ; Melanoma - drug therapy ; Monoclonal antibodies ; Pharmacology. Drug treatments ; Quality of life ; Recombinant Proteins ; Risk groups ; Toxicity</subject><ispartof>Journal of investigative dermatology, 1990-12, Vol.95 (6), p.S185-S187</ispartof><rights>1990 The Society for Investigative Dermatology, Inc</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-74809113da0d68bb884726c2536f85e4e40460a21b41b29c69f5179e754066583</citedby><cites>FETCH-LOGICAL-c554t-74809113da0d68bb884726c2536f85e4e40460a21b41b29c69f5179e754066583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23929,23930,25139,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19627824$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1701806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McLeod, G.R.</creatorcontrib><creatorcontrib>Thomson, D.B.</creatorcontrib><creatorcontrib>Hersey, P.</creatorcontrib><title>Clinical Evaluation of Interferons in Malignant Melanoma</title><title>Journal of investigative dermatology</title><addtitle>J Invest Dermatol</addtitle><description>The evaluation of interferons in the treatment of malignant melanoma has been mainly in the treatment of advanced disease using interferons as the sole agent or in combination with other agents. Studies of the value of interferons as adjuvant therapy in high-risk primary melanoma patients are necessary, but no results have been published to date. Human interferon alpha produces low response rates as a sole agent, but in combination with cimetidine, a 30% response rate has been achieved. Recombinant alpha interferons give responses of 15%-20% in advanced melanomas, and combination with cimetidine does not enhance the response rate.
Recombinant alpha interferons have been used in combination with other interferons, cimetidine, monoclonal antibodies, and cytotoxics, with either no or small improvement in response rates. DTIC with recombinant interferon alpha-2a has been shown to produce objective response rates of 26%, with low toxicity and maintenance of quality of life. A randomized trial with DTIC as the sole agent, compared with combination treatment, is being conducted to determine the significance of this finding.</description><subject>Adjuvants</subject><subject>alpha -Interferon</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cimetidine</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Cytotoxicity</subject><subject>Dacarbazine - administration & dosage</subject><subject>Dermatology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Forecasting</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interferon</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferons - therapeutic use</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - drug therapy</subject><subject>Monoclonal antibodies</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of life</subject><subject>Recombinant Proteins</subject><subject>Risk groups</subject><subject>Toxicity</subject><issn>0022-202X</issn><issn>1523-1747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMouq7-A4VeBC_VSZqvXgRZ_AIXLwreQppOJdJN16QV_Pe27OLezGUg7zvvzDyEnFG4ouO7poIVOVVcXeGaMq2EANgjs7_vfTIDYCxnwN6PyHFKnwBUcqEPySFVQDXIGdGL1gfvbJvdfdt2sL3vQtY12VPoMTYYu5AyH7Klbf1HsKHPltja0K3sCTlobJvwdFvn5O3-7nXxmD-_PDwtbp9zJwTvc8U1lJQWtYVa6qrSmismHROFbLRAjhy4BMtoxWnFSifLRlBVohIcpBS6mJPLTe46dl8Dpt6sfHLYjltgNyQzXi5AF6WarHxjdbFLKWJj1tGvbPwxFMyEzExszMTG7JCNbefbCUO1wnrXtGE06hdb3aYRVBNtcD7tbKVkSjO-ywm2HyL-GYSkTBVTzs1GxxHXt8dokvMYHNY-outN3fn_F_0FWYqOzw</recordid><startdate>19901201</startdate><enddate>19901201</enddate><creator>McLeod, G.R.</creator><creator>Thomson, D.B.</creator><creator>Hersey, P.</creator><general>Elsevier Inc</general><general>Nature Publishing</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19901201</creationdate><title>Clinical Evaluation of Interferons in Malignant Melanoma</title><author>McLeod, G.R. ; Thomson, D.B. ; Hersey, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-74809113da0d68bb884726c2536f85e4e40460a21b41b29c69f5179e754066583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adjuvants</topic><topic>alpha -Interferon</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cimetidine</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Cytotoxicity</topic><topic>Dacarbazine - administration & dosage</topic><topic>Dermatology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Forecasting</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interferon</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferons - therapeutic use</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - drug therapy</topic><topic>Monoclonal antibodies</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of life</topic><topic>Recombinant Proteins</topic><topic>Risk groups</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McLeod, G.R.</creatorcontrib><creatorcontrib>Thomson, D.B.</creatorcontrib><creatorcontrib>Hersey, P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of investigative dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McLeod, G.R.</au><au>Thomson, D.B.</au><au>Hersey, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Evaluation of Interferons in Malignant Melanoma</atitle><jtitle>Journal of investigative dermatology</jtitle><addtitle>J Invest Dermatol</addtitle><date>1990-12-01</date><risdate>1990</risdate><volume>95</volume><issue>6</issue><spage>S185</spage><epage>S187</epage><pages>S185-S187</pages><issn>0022-202X</issn><eissn>1523-1747</eissn><coden>JIDEAE</coden><abstract>The evaluation of interferons in the treatment of malignant melanoma has been mainly in the treatment of advanced disease using interferons as the sole agent or in combination with other agents. Studies of the value of interferons as adjuvant therapy in high-risk primary melanoma patients are necessary, but no results have been published to date. Human interferon alpha produces low response rates as a sole agent, but in combination with cimetidine, a 30% response rate has been achieved. Recombinant alpha interferons give responses of 15%-20% in advanced melanomas, and combination with cimetidine does not enhance the response rate.
Recombinant alpha interferons have been used in combination with other interferons, cimetidine, monoclonal antibodies, and cytotoxics, with either no or small improvement in response rates. DTIC with recombinant interferon alpha-2a has been shown to produce objective response rates of 26%, with low toxicity and maintenance of quality of life. A randomized trial with DTIC as the sole agent, compared with combination treatment, is being conducted to determine the significance of this finding.</abstract><cop>Danvers, MA</cop><pub>Elsevier Inc</pub><pmid>1701806</pmid><doi>10.1111/1523-1747.ep12875500</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-202X |
| ispartof | Journal of investigative dermatology, 1990-12, Vol.95 (6), p.S185-S187 |
| issn | 0022-202X 1523-1747 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1285083978 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adjuvants alpha -Interferon Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cimetidine Clinical trials Clinical Trials as Topic Cytotoxicity Dacarbazine - administration & dosage Dermatology Dose-Response Relationship, Drug Forecasting Humans Immunomodulators Interferon Interferon alpha-2 Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Interferons - therapeutic use Medical sciences Melanoma Melanoma - drug therapy Monoclonal antibodies Pharmacology. Drug treatments Quality of life Recombinant Proteins Risk groups Toxicity |
| title | Clinical Evaluation of Interferons in Malignant Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Evaluation%20of%20Interferons%20in%20Malignant%20Melanoma&rft.jtitle=Journal%20of%20investigative%20dermatology&rft.au=McLeod,%20G.R.&rft.date=1990-12-01&rft.volume=95&rft.issue=6&rft.spage=S185&rft.epage=S187&rft.pages=S185-S187&rft.issn=0022-202X&rft.eissn=1523-1747&rft.coden=JIDEAE&rft_id=info:doi/10.1111/1523-1747.ep12875500&rft_dat=%3Cproquest_cross%3E1285083978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1285083978&rft_id=info:pmid/1701806&rft_els_id=S0022202X9091218Z&rfr_iscdi=true |